The Ipamorelin + CJC-1295 stack — why everyone runs it
3 min read · Uplevel editorial
There's a moment in most people's introduction to GH peptides when they discover that nobody seems to use ipamorelin alone. Every forum, every compounding clinic protocol, every practitioner guide points to the same pairing: ipamorelin with CJC-1295. The combination has become so standard that the two compounds are often discussed as though they're a single thing. But the reason this combination became dominant is not arbitrary, and understanding the mechanism behind it explains why the pairing is more than a convention — it's mechanistic logic that follows from how growth hormone release actually works.
Your pituitary receives two competing inputs that govern GH secretion. One is GHRH — growth hormone-releasing hormone, produced in the hypothalamus — which signals the pituitary to release GH. The other is somatostatin, also from the hypothalamus, which signals the pituitary to stop. These two signals are in constant dynamic tension, and the GH pulse you produce at any given moment reflects the current balance between them. There's also a third pathway: the ghrelin receptor, GHS-R1a, which can stimulate GH release through a distinct molecular mechanism that operates somewhat independently of the GHRH/somatostatin balance.
This three-pathway architecture is why the combination makes biological sense.
Ipamorelin acts on the ghrelin receptor. CJC-1295 — in its most commonly used no-DAC form, also called Mod GRF 1-29 — acts on the GHRH receptor. These are not the same receptor and they are not the same signaling pathway, though they converge on the same downstream outcome: growth hormone secretion from pituitary somatotroph cells. When you activate both pathways simultaneously, the GH release you get is greater than what either compound produces on its own. This is synergism in the precise sense of the word — not additive, but multiplicative, because two distinct pathways are hitting the same pituitary cells at the same time.
The research literature on this is sparse in terms of human clinical trials specifically evaluating the combination, but the synergistic effect of combining GHRH-pathway and ghrelin-pathway stimulation has been demonstrated in studies of other compound pairs and is well-supported mechanistically. The logic is solid enough that clinicians working in the peptide space have adopted the pairing as standard without waiting for a combination-specific Phase III trial — a decision that reflects the state of evidence in this field more broadly, where mechanistic reasoning and clinical observation do significant work that formal trials haven't yet covered.
The typical dosing framework that has emerged from clinical practice involves subcutaneous injection of 100 to 300 micrograms of each compound, administered together, two to three times daily. The timing is built around naturally occurring GH pulse windows. The largest and most therapeutically significant pulse occurs in the first one to two hours of deep sleep, which makes a pre-sleep injection the most consistently used timing point. A morning injection taken fasted — before the first meal, when insulin levels are low — captures a second window: insulin suppresses GH release, and administering GH secretagogues when insulin is low allows for a larger GH response. A post-workout injection takes advantage of the exercise-induced GH pulse window, layering secretagogue stimulation onto the training signal.
Why does insulin matter? Growth hormone and insulin are physiologically antagonistic in certain respects. High insulin — the state after a carbohydrate-containing meal — blunts GH release and increases somatostatin activity. Timing secretagogue injections to low-insulin windows is not a minor refinement; it can substantially affect the magnitude of the GH response. This is one of the practical considerations that often gets lost when people focus on dose and frequency while ignoring the metabolic context of injection timing.
The cycling debate is one of the genuinely unresolved questions in this space. Some practitioners and users run the ipamorelin + CJC-1295 combination continuously without interruption for months. Others follow a five-days-on, two-days-off pattern, or a five-weeks-on, two-weeks-off schedule at larger time scales. The rationale for cycling is largely theoretical: the concern is that sustained receptor stimulation might lead to receptor downregulation — a reduced response over time as the pituitary adapts to chronic signaling input. In practice, this concern has not been definitively demonstrated with these specific compounds at typical clinical doses, and some practitioners report that their patients maintain response on continuous protocols.
The reason this stack became the default comes down to the architecture of GH release itself: two pathways, two receptors, one pituitary, and a combination that activates both at once to produce a response neither compound achieves alone. That the pairing became standard on mechanistic reasoning and consistent clinical observation rather than a dedicated combination trial is characteristic of this whole field, where the biology is well understood and the formal trials lag behind it. Neither ipamorelin nor CJC-1295 no-DAC is FDA-approved, and the question of whether the stack fits a given goal — and how to track IGF-1 over time — belongs with a prescribing provider. The synergy is real on paper; what it means for any individual is a question better answered with measurement than assumption.
Frequently asked